PET Insert banner

Applications

The PET Insert is operated by Paravision 360 with the trusted Paravision appearance and workflow allowing MRI users to followfamiliar MR imaging workflows and therefore start obtaining valuable PET/MR data almost immediately. The first system was installed in August 2016 in a 7 Tesla system atthe Katholieke Universiteit in Leuven, Belgium under the guidance of Christophe Deroose, Ph.D., Professor of Nuclear Medicine. Their initial imaging highlights the value of simultaneous PET/MR in studies involving structure/function in both tumor gross anatomy and tumor micro-environment. The potential of multi-parametric analysis, as well as simultaneous brain and cardiac imaging are also demonstrated.

Neurology in Rats

PET MRI Rat Brain CortecesPET MRI Whole Body Rat

18 FDG PET dynamic imaging with focus on neurology. Total body PET imaging: The large static PET FOV enables to simultaneously assess the tracer biodistribution in the whole body enabling kinetic analysis. Top image: the high PET resolution allows for this brain detail showing predominant tracer uptake in brain cortices. Bottom image: kidney function in excreting tracer's metabolites.

Glioma Tumor Development in Mice

PETInsert fig 5
Courtesy: Dr. Uwe Himmelreich, Dr. Matteo Riva, Dr. Willy Gsell, Dr. Cindy Casteels, Molecular Small Animal Imaging Center (MoSAIC), University hospital of Leuven, Belgium

•Early stage mouse glioma (5000 CT-2A cells, 8 days post injection) •Earliest detection of sub-mm³ tumors with superior high-field MRI resolution and soft tissue contrast •Tumor volume extracted from MRI: ~ 0.59 mm3 •Precise definition of the ROI based on high-field MRI allows PET tumor studies at the earliest stage

Characterization of Ovarian Tumour Development and Microenvironment

PET MRI tumour Microenvironment
Courtesy: S. Belderbos, K. Govaerts, A. Croitor Sava, et.al., KU Leuven, Leuven, Belgium

•Limited translation of nanoparticle (NPs) therapy to clinic partly because of the large tumour heterogeneity. •Characterization of tumour growth and microenvironment could potentially determine the ideal time window to initiate NP based therapy. •SKOV-3 xenografts (n=9) were generated after subcutaneous injection of 107 firefly luciferase-positive cells in nude mice. •Tumour microstructure, vascularization and perfusion were characterized by 1h static 18F-FDG (3-7 MBq) PET scan simultaneously with a 3D T2-weighted RARE MRI ØBased on the study, week 4 appeared to be the ideal time window to initialize NP therapy in this tumour model.

Tumor Heterogeneity Imaging in Mice

PETInsert fig 4
Courtesy: Sarah Belderbos, Dr. Uwe Himmelreich, Dr. Willy Gsell, Dr. Cindy Casteels, Molecular Small Animal Imaging Center (MoSAIC), University hospital of Leuven, Belgium

•Mouse Xenograft model: Human ovarian tumor cells (SKOV3) were injected subcutaneously in athymic nude mice •Images were taken four weeks after engraftment •T2W-RARE and FDG PET overlays •Both MRI and PET show tumor heterogeneity

Whole body Simultaneous PET/MRI in Mice

PET MRI Sequential Whole body mouse
Courtesy: Dr W Gsell and Prof U Himmelreich, KU Leuven, Belgium

•Large FOV in both modalities allows for simultaneous PET/MR whole body mouse imaging •T1 weighted MRI and PET uptake were dynamically imaged for 65 min Due to the large FOV of 148 mm the biodistribution of different organs can be studied simultaneously

Stroke Imaging in Mice

PET_MRI_Ischemia.bmp
Courtesy: Dr. Uwe Himmelreich, Dr. Willy Gsell, Dr. Cindy Casteels , Molecular Small Animal Imaging Center (MoSAIC), University hospital of Leuven, Belgium

Ischemic MCAO mouse model (intraluminal transient MCAO, 24 h post occlusion / reperfusion) High resolution MR enables the location of the lesion including the vasogenic edema corresponding to the low FDG uptake (core of the lesion)